LOS ANGELES, May 25, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against
Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX) concerning possible violations of federal securities laws between
March 30, 2017 and May 11, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during
the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an
attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed
to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued
a report on the Company called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced that the report was
withdrawn due to “material inaccuracies.” On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on
administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the
materially inaccurate research report. When this information was announced, Akari shares fell in value, which harmed investors
according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’
rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical
rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 brian@lundinlawpc.com http://lundinlawpc.com/